NCT06518668View on ClinicalTrials.gov

A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus

PHASE1RecruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2040

Conditions
Systemic Lupus Erythematosus
Interventions
BIOLOGICAL

NKX019

NKX019 is an investigational allogeneic CD19-Directed CAR NK. NKX019 will be administered at a dose of 1 × 109 CAR NK cells (dose normalized for weight for subjects ≤ 50 kg) administered IV.

DRUG

Cyclophosphamide LD

"Cy dose of 1 g/m2 administered IV over 30 to 60 minutes for the purpose of Lymphodepletion Therapy. Cyclophosphamide will help prepare your body to receive the treatment by decreasing the cells from your immune system to make space for the NKX019 cells.~(non-experimental)"

Trial Locations (1)

10032

RECRUITING

Columbia University Irving Medical Center, New York

All Listed Sponsors
lead

Columbia University

OTHER